99 related articles for article (PubMed ID: 16674939)
1. Dopamine uptake and cocaine binding mechanisms: the involvement of charged amino acids from the transmembrane domains of the human dopamine transporter.
Dar DE; Metzger TG; Vandenbergh DJ; Uhl GR
Eur J Pharmacol; 2006 May; 538(1-3):43-7. PubMed ID: 16674939
[TBL] [Abstract][Full Text] [Related]
2. Dopamine transporter transmembrane domain polar mutants: DeltaG and DeltaDeltaG values implicate regions important for transporter functions.
Itokawa M; Lin Z; Cai NS; Wu C; Kitayama S; Wang JB; Uhl GR
Mol Pharmacol; 2000 Jun; 57(6):1093-103. PubMed ID: 10825379
[TBL] [Abstract][Full Text] [Related]
3. Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine.
Chen N; Zhen J; Reith ME
J Neurochem; 2004 May; 89(4):853-64. PubMed ID: 15140185
[TBL] [Abstract][Full Text] [Related]
4. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue.
Ukairo OT; Bondi CD; Newman AH; Kulkarni SS; Kozikowski AP; Pan S; Surratt CK
J Pharmacol Exp Ther; 2005 Aug; 314(2):575-83. PubMed ID: 15879005
[TBL] [Abstract][Full Text] [Related]
5. Importance of valine at position 152 for the substrate transport and 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane binding of dopamine transporter.
Lee SH; Chang MY; Lee KH; Park BS; Lee YS; Chin HR; Lee YS
Mol Pharmacol; 2000 May; 57(5):883-9. PubMed ID: 10779370
[TBL] [Abstract][Full Text] [Related]
6. Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors.
Loland CJ; Desai RI; Zou MF; Cao J; Grundt P; Gerstbrein K; Sitte HH; Newman AH; Katz JL; Gether U
Mol Pharmacol; 2008 Mar; 73(3):813-23. PubMed ID: 17978168
[TBL] [Abstract][Full Text] [Related]
7. Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells.
Chen N; Reith ME
J Neurochem; 2007 Apr; 101(2):377-88. PubMed ID: 17250655
[TBL] [Abstract][Full Text] [Related]
8. Dopamine transporter tryptophan mutants highlight candidate dopamine- and cocaine-selective domains.
Lin Z; Wang W; Uhl GR
Mol Pharmacol; 2000 Dec; 58(6):1581-92. PubMed ID: 11093799
[TBL] [Abstract][Full Text] [Related]
9. Dissociation of high-affinity cocaine analog binding and dopamine uptake inhibition at the dopamine transporter.
Wang W; Sonders MS; Ukairo OT; Scott H; Kloetzel MK; Surratt CK
Mol Pharmacol; 2003 Aug; 64(2):430-9. PubMed ID: 12869648
[TBL] [Abstract][Full Text] [Related]
10. Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition.
Lin Z; Wang W; Kopajtic T; Revay RS; Uhl GR
Mol Pharmacol; 1999 Aug; 56(2):434-47. PubMed ID: 10419565
[TBL] [Abstract][Full Text] [Related]
11. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate.
Chen R; Han DD; Gu HH
J Neurochem; 2005 Jul; 94(2):352-9. PubMed ID: 15998286
[TBL] [Abstract][Full Text] [Related]
12. Inhibitive effects of Fructus Psoraleae extract on dopamine transporter and noradrenaline transporter.
Zhao G; Li S; Qin GW; Fei J; Guo LH
J Ethnopharmacol; 2007 Jul; 112(3):498-506. PubMed ID: 17555897
[TBL] [Abstract][Full Text] [Related]
13. Gain of function mutants reveal sites important for the interaction of the atypical inhibitors benztropine and bupropion with monoamine transporters.
Mortensen OV; Amara SG
J Neurochem; 2006 Sep; 98(5):1531-40. PubMed ID: 16923164
[TBL] [Abstract][Full Text] [Related]
14. Proline mutations induce negative-dosage effects on uptake velocity of the dopamine transporter.
Lin Z; Uhl GR
J Neurochem; 2005 Jul; 94(1):276-87. PubMed ID: 15953370
[TBL] [Abstract][Full Text] [Related]
15. A pincer-like configuration of TM2 in the human dopamine transporter is responsible for indirect effects on cocaine binding.
Sen N; Shi L; Beuming T; Weinstein H; Javitch JA
Neuropharmacology; 2005 Nov; 49(6):780-90. PubMed ID: 16216288
[TBL] [Abstract][Full Text] [Related]
16. Human dopamine transporter gene variation: effects of protein coding variants V55A and V382A on expression and uptake activities.
Lin Z; Uhl GR
Pharmacogenomics J; 2003; 3(3):159-68. PubMed ID: 12815364
[TBL] [Abstract][Full Text] [Related]
17. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding.
Kitayama S; Shimada S; Xu H; Markham L; Donovan DM; Uhl GR
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7782-5. PubMed ID: 1502198
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of dopamine and psychoactive drugs on dopamine transporter phosphorylation and regulation.
Gorentla BK; Vaughan RA
Neuropharmacology; 2005 Nov; 49(6):759-68. PubMed ID: 16181646
[TBL] [Abstract][Full Text] [Related]
19. Zinc regulates the dopamine transporter in a membrane potential and chloride dependent manner.
Pifl C; Wolf A; Rebernik P; Reither H; Berger ML
Neuropharmacology; 2009 Feb; 56(2):531-40. PubMed ID: 19000913
[TBL] [Abstract][Full Text] [Related]
20. Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism.
Lin Z; Uhl GR
Mol Pharmacol; 2002 Apr; 61(4):885-91. PubMed ID: 11901228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]